Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)LeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - Other
Ratios

Amylyx Pharmaceuticals (AMLX) Accumulated Depreciation & Amortization (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Accumulated Depreciation & Amortization data on record, last reported at $1.6 million in Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 14.35% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, up 14.35%, while the annual FY2025 figure was $1.6 million, 14.35% up from the prior year.
  • Accumulated Depreciation & Amortization reached $1.6 million in Q4 2025 per AMLX's latest filing, up from $1.4 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $1.6 million in Q4 2023 and bottomed at $53000.0 in Q4 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $1.0 million, with a median of $1.4 million recorded in 2024.
  • Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 918.87% in 2022, then fell 16.52% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $53000.0 in 2021, then surged by 918.87% to $540000.0 in 2022, then surged by 201.48% to $1.6 million in 2023, then decreased by 16.52% to $1.4 million in 2024, then rose by 14.35% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $1.6 million in Q4 2025, $1.4 million in Q4 2024, and $1.6 million in Q4 2023.